Zydus Lifesciences Limited — Updates, 17-04-2025: Press Release

Zydus Lifesciences has executed undertakings to tender 2,236,911 shares of Amplitude Surgical, representing approximately 4.7% of its capital and voting rights, as part of its planned tender offer. This follows an earlier announcement regarding the acquisition of an 85.6% stake from PAI Partners, management, and two minority shareholders, positioning Zydus to secure over 90% of Amplitude's equity by the conclusion of the tender process. The acquisition is anticipated to be finalized by June 2025, with the draft tender offer submitted to the relevant regulatory body following the necessary approvals. Investors should monitor this acquisition closely, as it could lead to significant strategic advantages for Zydus Lifesciences in the medical sector.